GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cipla Ltd (BOM:500087) » Definitions » YoY EBITDA Growth

Cipla (BOM:500087) YoY EBITDA Growth : 16.73% (As of Mar. 2025)


View and export this data going back to 1992. Start your Free Trial

What is Cipla YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Cipla's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was 16.73%.

Cipla's EBITDA per Share for the three months ended in Mar. 2025 was ₹22.61.

Cipla YoY EBITDA Growth Historical Data

The historical data trend for Cipla's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cipla YoY EBITDA Growth Chart

Cipla Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.49 3.18 12.26 32.76 16.74

Cipla Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.22 14.97 8.67 27.17 16.73

Cipla YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Cipla's YoY EBITDA Growth for the fiscal year that ended in Mar. 2025 is calculated as:

YoY EBITDA Growth (A: Mar. 2025 )
=(EBITDA per Share (A: Mar. 2025 )-EBITDA per Share (A: Mar. 2024 ))/ | EBITDA per Share (A: Mar. 2024 ) |
=(98.862-84.689)/ | 84.689 |
=16.74 %

Cipla's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY EBITDA Growth (Q: Mar. 2025 )
=(EBITDA per Share (Q: Mar. 2025 )-EBITDA per Share (Q: Mar. 2024 )) / | EBITDA per Share (Q: Mar. 2024 )) |
=(22.609-19.369)/ | 19.369 |
=16.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cipla YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Cipla's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Cipla Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cipla Ltd (BOM:500087) » Definitions » YoY EBITDA Growth
Comparable Companies
NSE:TORNTPHARM BOM:500124 BOM:543904 BOM:532321 BOM:500257 NSE:AUROPHARMA NSE:DIVISLAB BOM:500488 NSE:ALKEM BOM:543064 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ HKSE:03692 XTAE:TEVA SHSE:688506
Traded in Other Exchanges
CIPLA:India
Address
Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, IND, 400 013
Website
https://www.cipla.com
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.

Cipla Headlines

No Headlines